



Xencor, Inc.
 Investor Relations Department
 111 West Lemon Avenue
 Monrovia, CA 91016
 United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: XNCR	
Last Trade:	21.53
Trade Time:	4:00 PM ET Dec 15, 2017
Change:	0.52 (+2.475%)
Day Range	20.89 - 21.67
52-Week Range	18.55 - 28.64
Volume	602,278

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Since Xencor's founding in 1997, investors have been drawn to our remarkable scientific capabilities around monoclonal antibodies and solid intellectual property which serve as the engine behind our drug development programs. Currently, 11 candidates that have been engineered with Xencor's XmAb® technology are in clinical development by us or with partners. Xencor's internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1a development fo... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 5, 2017
[Xencor Receives Milestone Payment from Amgen](#)
- Nov 8, 2017
[Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer \(SITC\) 2017 Annual Meeting](#)
- Nov 7, 2017
[Xencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update](#)
- Nov 4, 2017
[Xencor Presents Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease \(IgG4-RD\) at the American College of Rheumatology 2017 Annual Meeting](#)
- Nov 1, 2017
[Xencor to Present at Upcoming Investor Conferences](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 1, 2017
[Annual Report \(10-K\)](#)
- May 1, 2017
[Proxy Statement \(DEF 14A\)](#)
- Nov 8, 2017
[Quarterly Report \(10-Q\)](#)
- Aug 7, 2017
[Quarterly Report \(10-Q\)](#)
- May 10, 2017
[Quarterly Report \(10-Q\)](#)